QuidelOrtho's stock plummeted 24.69% during intraday trading on Thursday, reflecting significant selling pressure.
The sharp decline followed analyst actions, notably UBS adjusting its price target for QuidelOrtho down to $30 from $35 while maintaining a Neutral rating. This downward revision likely contributed to negative market sentiment toward the stock.
Other analyst updates included Citigroup raising its price target to $30 from $23, but this positive move was overshadowed by the UBS target cut during the trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments